Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Yuan Z, Claros CS, Suzuki M, Maggi EC, Kaner JD, Kinstlinger N, et al. Loss of MEN1 activates DNMT1 implicating DNA hypermethylation as a driver of MEN1 tumorigenesis. Oncotarget. 2016;7(11):12633-50.

Carden MA, Caltharp S, Yee ME, Haight AE, Westblade LF, Park S. Recipient-derived EBV-positive Monomorphic Plasmacytoma Type Posttransplant Lymphoproliferative Disorder After Allogeneic Stem Cell Transplant for Severe Aplastic Anemia: A Case Report. J Pediatr Hematol Oncol. 2016;38(8):e310-e314.

Inayat F, Law JK, Myers-Gurevitch PM, Seshan SV, Perlman AS. Minimal change disease: an unusual presentation of marginal zone MALT lymphoma. Clin Nephrol. 2016;85(3):184-8.

Santo EE, Paik J. FOXO3a & haematopoietic stem cells: Goodbye PI3K, hello SIRT1? Cell Cycle. 2016;15(7):879-80.

Welsh KJ, Hermane AT, Zhao Z. Is This Patient Pregnant? Clin Chem. 2016;62(8):1163-4.

Shanmugam V, Geraghty B, DeSimone RA, Hoda RS. Diagnostic value of positive urinary cytology in the detection of recurrent urothelial carcinoma: 10-Year Experience at the Papanicolaou Cytology Laboratory. Diagn Cytopathol. 2016;44(12):975-979.

Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559-63.

Davis JE, Nemesure B, Mehmood S, Nayi V, Burke S, Brzostek SR, et al. Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ. Appl Immunohistochem Mol Morphol. 2016;24(1):20-5.

Xylinas E, Hassler MR, Zhuang D, Krzywinski M, Erdem Z, Robinson BD, et al. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer. Biomolecules. 2016;6(3).

Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, et al. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016;538(7625):397-401.